Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women

• Main Authors: Annie Wai Chee Kung, Ichramsjah A. Rachman, John M.F. Adam, Djoko Roeshadi, Tito Torralba, Sandra Navarra, Zayda Gamilla, Arthur Cañete, Miles de la Rosa, Keh Sung Tsai, Hsiao Yi Lin, Yung Kuei Soong, Joung Liang Lan, Horng Chaung Hsu, Shih Te Tu, Ruey Mo Lin, Pongsak Yuktanandana, Thawee Songpatanasilp, Srihatach Ngarmukos, Sugree Soontrapa, Suppasin Soontrapa, Sattaya Rojanasthien, Sirichai Luevitoonvechkij, Taninnit Leerapan, Adelin Albert, Sophie Vanbelle
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=69149106711&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/59806
• Institution: Chiang Mai University

Aim: his study assesses the impact of serum carboxy-terminal collagen crosslinks (CTX) bone marker feedback (BMF) on adherence to ibandronate treatment in Asian postmenopausal women with osteoporosis. Methods: This was a 12-month (6-monthly phased), randomized, prospective, open-label, multi-center study conducted in 596 (of 628 enrolled) postmenopausal women with osteoporosis (≤ 85 years old) who were naïve, lapsed, or current bisphosphonate users. Patients were randomized into two arms: serum CTX BMF at 3 months versus no-BMF. Once-monthly 150 mg ibandronate tablet was administered for 12 months and adherence to therapy was assessed at 6 and 12 months. In addition, patient satisfaction and safety of ibandronate treatment were also assessed. Results: Serum CTX BMF at 3 months showed no impact on adherence. The proportions of adherent patients were comparable in the BMF versus no-BMF arms (92.6% vs. 96.0%, P = 0.16); overall, serum CTX levels were similar for adherent and non-adherent patients. However, BMF patients felt more informed about their osteoporosis (P < 0.001) and more satisfied (P < 0.01) than no-BMF patients. Conclusions: The Asian postmenopausal osteoporosis patients in this study had a high adherence rate to once-monthly ibandronate therapy. Use of serum CTX BMF had no further impact on increasing adherence, but increased treatment satisfaction. © 2009 Asia Pacific League of Associations for Rheumatology and Blackwell Publishing Asia Pty Ltd.